Evidence map›Paper›PMID 31406134›Full record

ArticleScientific reports2019

Reproducibility via coordinated standardization: a multi-center study in a Shank2 genetic rat model for Autism Spectrum Disorders.

María Arroyo-Araujo, Radka Graf, Martine Maco, Elsbeth van Dam, Esther Schenker, Wilhelmus Drinkenburg, Bastijn Koopmans, Sietse F de Boer, Michaela Cullum-Doyle, Lucas P J J Noldus and 6 more

Open access · goldAbstract readMulticenter Study
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 2 pooled it
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 32 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 7 institutions in 5 countries.

María Arroyo-AraujoGroningen Institute for Evolutionary Life Sciences, University of Groningen, Groningen, The Netherlands.
Radka GrafNeuroscience and Pain Research Unit, Pfizer Inc., Cambridge, MA, USA.
Martine MacoRoche Innovation Center Basel, Basel, Switzerland.
Elsbeth van DamNoldus Information Technology BV, Wageningen, The Netherlands.
Esther SchenkerInstitut de Recherches Servier, Croissy-sur-Seine, France.
Wilhelmus DrinkenburgJanssen Research & Development, Janssen Pharmaceutica NV, Beerse, Belgium.
Bastijn KoopmansSylics Synaptologics BV, Amsterdam, The Netherlands.
Sietse F de BoerGroningen Institute for Evolutionary Life Sciences, University of Groningen, Groningen, The Netherlands.
Michaela Cullum-DoyleNeuroscience and Pain Research Unit, Pfizer Inc., Cambridge, MA, USA.
Lucas P J J NoldusNoldus Information Technology BV, Wageningen, The Netherlands.
Maarten LoosSylics Synaptologics BV, Amsterdam, The Netherlands.ORCID http://orcid.org/0000-0003-1629-2928
Wil van DommelenNoldus Information Technology BV, Wageningen, The Netherlands.
Will SpoorenNeuroscience and Pain Research Unit, Pfizer Inc., Cambridge, MA, USA.
Barbara BiemansRoche Innovation Center Basel, Basel, Switzerland.
Derek L BuhlNeuroscience and Pain Research Unit, Pfizer Inc., Cambridge, MA, USA.
Martien J KasGroningen Institute for Evolutionary Life Sciences, University of Groningen, Groningen, The Netherlands. m.j.h.kas@rug.nl.ORCID http://orcid.org/0000-0002-4471-8618
Pfizer (United States) · USNoldus Information Technology · NLUniversity of Groningen · NLRoche (Switzerland) · CHSylics (Netherlands) · NLJanssen (Belgium) · BEServier (France) · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inconsistent findings between laboratories are hampering scientific progress and are of increasing public concern. Differences in laboratory environment is a known factor contributing to poor reproducibility of findings between research sites, and well-controlled multisite efforts are an important next step to identify the relevant factors needed to reduce variation in study outcome between laboratories. Through harmonization of apparatus, test protocol, and aligned and non-aligned environmental variables, the present study shows that behavioral pharmacological responses in Shank2 knockout (KO) rats, a model of synaptic dysfunction relevant to autism spectrum disorders, were highly replicable across three research centers. All three sites reliably observed a hyperactive and repetitive behavioral phenotype in KO rats compared to their wild-type littermates as well as a dose-dependent phenotype attenuation following acute injections of a selective mGluR1 antagonist. These results show that reproducibility in preclinical studies can be obtained and emphasizes the need for high quality and rigorous methodologies in scientific research. Considering the observed external validity, the present study also suggests mGluR1 as potential target for the treatment of autism spectrum disorders.

Indexed as

Disease Models, AnimalAnimalsAutism Spectrum DisorderCross-Over StudiesGene Knockdown TechniquesMaleNerve Tissue ProteinsRatsRats, Sprague-DawleyReproducibility of ResultsNerve Tissue ProteinsShank2 protein, rat

Identifiers

PMID31406134
PMCPMC6690904
OpenAlexW2968439389

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.